Vestmark Advisory Solutions Inc. Purchases Shares of 265,981 Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Vestmark Advisory Solutions Inc. purchased a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 265,981 shares of the company's stock, valued at approximately $8,110,000. Vestmark Advisory Solutions Inc. owned about 0.30% of Intellia Therapeutics at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. ARK Investment Management LLC increased its holdings in Intellia Therapeutics by 14.7% in the 4th quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company's stock worth $347,966,000 after buying an additional 1,463,820 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its position in Intellia Therapeutics by 3.7% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,520,295 shares of the company's stock valued at $111,312,000 after purchasing an additional 125,639 shares during the period. Wellington Management Group LLP boosted its holdings in Intellia Therapeutics by 1.4% in the third quarter. Wellington Management Group LLP now owns 2,651,994 shares of the company's stock worth $83,856,000 after purchasing an additional 36,630 shares during the last quarter. Federated Hermes Inc. grew its position in Intellia Therapeutics by 13.8% in the 4th quarter. Federated Hermes Inc. now owns 2,016,300 shares of the company's stock worth $61,477,000 after purchasing an additional 244,722 shares during the period. Finally, Rhenman & Partners Asset Management AB raised its stake in Intellia Therapeutics by 1,600.0% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 850,000 shares of the company's stock valued at $26,877,000 after buying an additional 800,000 shares during the last quarter. Institutional investors own 88.77% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Wolfe Research assumed coverage on Intellia Therapeutics in a research note on Thursday, February 15th. They issued a "peer perform" rating on the stock. The Goldman Sachs Group downgraded Intellia Therapeutics from a "buy" rating to a "neutral" rating and cut their price target for the company from $136.00 to $32.00 in a research note on Friday, February 23rd. Wedbush reiterated a "neutral" rating and issued a $29.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. Finally, Canaccord Genuity Group raised their price objective on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the stock a "buy" rating in a report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $67.00.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, EVP James Basta sold 2,297 shares of the company's stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $32.99, for a total value of $75,778.03. Following the completion of the transaction, the executive vice president now directly owns 81,571 shares in the company, valued at approximately $2,691,027.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 3.00% of the stock is owned by corporate insiders.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA traded up $0.33 during midday trading on Friday, reaching $23.60. The stock had a trading volume of 1,294,988 shares, compared to its average volume of 1,217,743. Intellia Therapeutics, Inc. has a 12-month low of $19.37 and a 12-month high of $47.48. The stock has a 50-day moving average of $26.06 and a 200-day moving average of $27.29. The company has a market capitalization of $2.28 billion, a price-to-earnings ratio of -4.36 and a beta of 1.85.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($1.46) EPS for the quarter, beating analysts' consensus estimates of ($1.47) by $0.01. The business had revenue of ($1.92) million for the quarter, compared to analysts' expectations of $15.10 million. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. During the same period last year, the firm earned ($1.40) earnings per share. As a group, analysts forecast that Intellia Therapeutics, Inc. will post -5.57 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.